Amitraz, queen spermathecae and microbiota: interpreting the 2026 data
Why queen sperm viability matters
The queen stores sperm acquired during mating in her spermatheca and uses it when laying eggs. The percentage of viable sperm is an important biological parameter, but on its own it is not a sufficient indicator of the queen’s future lifespan or colony productivity. Sperm quantity, environmental conditions, disease and worker behaviour also contribute to reproductive outcomes.
In 2026, a US research group examined the consequences of management-related exposure to amitraz and oxytetracycline on several parameters in adult queens and brood. The work’s main contribution is not a blanket condemnation of treatments, but the opportunity to distinguish measured effects on reproductive functions and microbiota.
Three experiments in an apiary setting
Metz and colleagues conducted three experiments at research facilities in North Carolina between 2022 and 2025. Groups exposed to products containing oxytetracycline or amitraz were compared with concurrent controls according to the research protocol. Queens were examined for morphological, sperm and microbiological characteristics; some observations concerned egg laying and brood survival.
The researchers analysed sperm viability using stains that distinguish live and dead cells, and studied bacterial communities through sequencing. Not every individual yielded usable samples for every analysis: after filtering, 53 queen microbiological samples were analysed. This detail is a reminder that the findings concern defined experimental groups, not a survey of every possible condition of product use.
Amitraz: the finding on stored sperm
In the 2023 comparison, median sperm viability was 87.3% in control queens and 65.4% in queens exposed to amitraz. The authors report a statistically significant difference for this indicator. This is a laboratory measurement of sperm viability in sampled queens, not the percentage of fertilised eggs or colony survival.
The same work found no significant difference in the number of eggs laid during the trial and no general effect on the brood-survival parameters examined. It is therefore incorrect to claim that exposure automatically caused sterility or egg-laying failure.
Oxytetracycline and gut microbiota
Queens from the oxytetracycline-exposed group showed no significant reduction in sperm viability compared with controls from the corresponding year. The authors instead observed a modest but statistically significant difference in gut bacterial community composition, measured as diversity between samples.
There was no detected reduction in diversity within individual communities, nor a simple relationship between microbiota changes and egg laying. This is an important example: “altered microbiota” does not automatically mean “sick queen”. Demonstrating a health effect requires functional links and measurements over appropriate periods.
The colony’s protective effect
The queen is fed and cared for by workers and carries out most of her activity near the brood. This can change the routes and intensity of exposure to substances compared with an individual treated directly in a laboratory. The authors propose that such social buffering helps explain some differences between laboratory and apiary experiments.
It does not guarantee an absence of risk. Rather, it shows why results obtained through direct exposure should not automatically be transferred to an entire colony, or vice versa. Dose, formulation, duration, climate, management and colony condition all change the picture.
Interpreting the relationship between health treatments and queen quality
Varroa and associated viruses pose real risks to colonies. Potential adverse effects of medicines cannot be discussed while ignoring the harm caused by failing to manage the parasite. Choices must be guided by authorised product instructions, veterinary prescriptions and actual hive conditions.
The research suggests maintaining attention to reproductive physiology even when treatment efficacy against Varroa is the immediate goal. It does not, however, provide a basis for arbitrarily stopping treatments or legitimise unauthorised antibiotic or acaricide use.
Assessment within a breeding programme
ESA Regine considers queen quality as a combination of traits: genetic origin, mating control where applicable, appropriate breeding management and progeny assessment. Sperm-related indicators are relevant to this approach, but do not replace observation of daughter-colony performance.
The cited research is independent of ESA Regine; we neither attribute these trials to the company nor claim that they certify the effectiveness of our practices. Rather, the work helps maintain a technical discussion grounded in evidence and its limitations.
Sample sizes and experimental units
In both 2022 and 2023, the authors established an apiary of 40 colonies for each year, divided into twenty receiving the treatment under study and twenty controls. The 2022 comparison concerned oxytetracycline; the 2023 comparison concerned amitraz. Queens came from stock of predominantly Italian ancestry, but did not represent a certified, homogeneous Apis mellifera ligustica population. The subsequent 2025 trial on egg laying and brood development comprised eighteen colonies randomly assigned to three groups of six, plus two excluded from assessment. Numbers must therefore be interpreted for each experiment and outcome separately.
The colony is the main unit of treatment assignment. Bees, sperm cells and microbial sequences measured within each queen are subsamples, not biological replicates of the apiary intervention. Moreover, hives in the first two years were arranged in rows: treatment allocation limited drifting, but creates possible location effects to consider. The three years and different endpoints make the study more informative than a trial on a few families, without constituting three perfectly interchangeable replicates.
Effect size and negative results
The 2023 comparison recorded median sperm viability of 87.3% in controls and 65.4% in the amitraz-exposed group, with dispersion expressed as median absolute deviations of 8.9 and 7.5 percentage points, respectively. The difference between medians is 21.9 percentage points; the authors’ test gives p = 0.01. In 2022, for oxytetracycline, the medians were 74.6% and 75.2%, with no statistically significant difference (p = 0.23). It is correct to say that amitraz lowered viability in that trial; inferring sterility, remaining egg-laying lifespan or increased queen replacement requires other measurements.
The egg-laying trial found no statistically significant effects on the number of worker eggs (p = 0.29) or drone eggs (p = 0.62). Increased survival of drones to pupation was reported in the oxytetracycline group, but only two colonies in that group successfully produced the drone eggs assessed: this limitation weakens the inference. It is incorrect to select only the value that appears favourable or unfavourable while ignoring actual sample sizes, null results and the extent of uncertainty.
Microbiota: what the sequences measure
Sequencing targeted the V4 region of the bacterial 16S rRNA gene: a technique for describing microbiota taxonomic composition, not a direct measurement of metabolism or reproductive health. After filtering and checks, 53 usable samples remained. Alpha diversity, describing variety within a single sample, did not differ significantly between groups. Beta diversity, comparing community composition, showed a modest change with oxytetracycline (p = 0.032), but not amitraz (p = 0.79). The reported analysis found no consistently differentiated taxa in within-year comparisons.
The researchers primarily assessed relative abundances: a percentage increase in one microbial group can also result from a decrease in another, without any increase in absolute cell numbers. Demonstrating clinically relevant dysbiosis would require functional measurements, absolute loads and independent correlations with health outcomes. This is essential both to avoid treating the absence of a significant taxonomic change as proof of complete harmlessness and, conversely, to avoid calling every statistical difference in composition a disease.
Practical implications and limits to transferability
The work is relevant to professional breeding because it describes a possible vulnerability of the queen’s sperm reserve to a health-management intervention. It does not, however, allow an alternative treatment schedule or a universal rule for queen replacement timing to be derived. Comparing the benefits of Varroa control with adverse risks must consider the authorised formulation, label compliance, parasite pressure and the whole season. Petit and Jack’s 2026 review documents highly heterogeneous sublethal effects across active substances, biological levels and test conditions.
Turning the experimental finding into a breeding recommendation would require replication across several regions and genetic lines, assessment of the dose actually reaching the queen, and longitudinal measurements of egg laying, brood fertility, replacement probability and colony productivity. Queens in the study were dissected for analysis, so those same individuals were not followed through to the end of their reproductive lives. This is a methodological limitation, not a flaw to conceal: a rigorous article must make it clear to readers.
Limitations and the need for further studies
The trials took place in a single geographical setting, with queens from different groups and years. Some brood indicators showed high variability and small sample sizes. Statistical differences observed in a single parameter need replication and integration with long-term outcomes.
It would be useful to follow queens over several seasons, assessing natural supersedure, egg-laying quality, sperm viability over time and differences between families in different environments. These measurements would allow a physiological finding to be translated into a more robust breeding assessment.
Frequently asked questions
Does amitraz make all queens sterile? No. The study found lower median sperm viability in the exposed group, but no significant halt in egg laying under the observed conditions.
Does this study suggest not treating Varroa? No. Health management remains necessary and must follow veterinary guidance and authorised medicine instructions. The data call for assessment of benefits and risks, not abandonment of parasite control.
Scientific sources
Claire – ESA Regine editorial team
Comments